Stock XLO XILIO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Xilio Therapeutics, Inc.

Equities

XLO

US98422T1007

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.09 USD +7.92% Intraday chart for Xilio Therapeutics, Inc. -5.22% +98.18%
Apr. 19 Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says MT
Apr. 01 Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says
MT
Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
GL
Xilio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Sector Update: Health Care Stocks Slide Late Afternoon
MT
Top Midday Gainers
MT
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures
MT
Top Premarket Gainers
MT
Xilio Shares Take Flight Premarket After Gilead Deal
DJ
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall
MT
Xilio Therapeutics : Corporate Update Call
PU
Gilead Sciences Signs Exclusive Development, Commercialization License for Xilio's Tumor-Activated IL-12
MT
Transcript : Xilio Therapeutics, Inc. - Special Call
Xilio Therapeutics Plans Private Placement, Job Cuts
DJ
Gilead Sciences in Exclusive License for Xilio Tumor-Activated IL-12 Program
DJ
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
GL
Xilio Therapeutics, Inc. Enters Exclusive License Agreement with Gilead Sciences, Inc
CI
Xilio Therapeutics, Inc. Plans Workforce Reduction
CI
Xilio Therapeutics, Inc. Reports Additional Data from Its Phase 2 Clinical Trial Evaluating XTX202
CI
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. XLO Stock
  4. News Xilio Therapeutics, Inc.